The leading European partnering event for early-stage deals and investment rounds in the Life Sciences field

NEW DESTINATION

MARSEILLE

FRANCE

8th edition DECEMBER 10 & 11 2019

www.biofit-event.com @BIOFIT_EVENT @BioFIT Event
BIOFIT AT A GLANCE

With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.

BIOFIT 2019 KEY FIGURES:

1,300+ DELEGATES
35+ COUNTRIES REPRESENTED
10,000+ MEETINGS GENERATED
100+ EXHIBITORS
80+ SPEAKERS
50+ INNOVATION PITCHERS

WELCOME

Since its first edition, in 2010, BioFIT has become the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field.

Today, we are very pleased to welcome you to Marseilles for the 8th edition of BioFIT, which has been developed, through the years, as the marketplace for pre-seed, seed and Series A investment in Life Sciences.

This edition will gather over 1,300 attendees from 35 countries, representing large companies, medium-sized businesses, start-ups as well as tech transfer organisations, academics and investors. Thanks to the quality and diversity of its participants, BioFIT looks certain to generate this year gain, excellent collaborating opportunities.

We wish you a fruitful and enjoyable two-day event, full of meeting and partnerships opportunities and we hope to see you next year in Strasbourg on December 1st and 2nd, 2020 for the 9th edition of BioFIT, where more meetings, deals and discoveries of early-stage innovations in Life Sciences!

Organisers:
Etienne Vervaecke
General Manager of Eurasanté and Clubster-NHL
Emilie Royere
General Manager of Eurobiomed
Marco Pintore
General Manager of BioValley France
ORGANISERS

www.eurasante.com  @Eurasante
Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 30,800 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within a European-wide scientific and medical site. Eurasanté also organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT [Life Sciences], MedFIT [MedTech, Diagnostic, Digital Health], NutrEvent [Food, Feed, Nutrition, Health] and AgeingFit [Healthy Ageing].

www.clubstersante.com  @ClubsterNSL
Clubster-Nutrition Health Longevity (NHL) is a dynamic network at the intersection of health, biotechnology and nutrition. Clubster-NHL aims to connect academia and industry partners around R&D projects. It focuses on the prevention and treatment of lifestyle-related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.

www.biovalley-france.com  @BioValleyFrance
Competitiveness cluster since 2005, BioValley France aims to federate, develop and promote the healthcare sector in the Grand Est region through innovation. The cluster is based on a dynamic network of companies, a leading academic and clinical research, as well as an integrated network of key stakeholders in innovation. BioValley France supports its members in their R&D Innovation approach and gives them access to high value-added expertise, in a market approach. The Cluster contributes to the networking of the various actors and the creation of regional, national and international partnerships. Finally, BioValley France actively participates in the territory’s structuring projects, such as Nextmed, which aims to create a Medical Technologies campus in Strasbourg that hosts an entire ecosystem of excellence dedicated to the development of tomorrow’s health technologies.

www.eurobiomed.com  @PoleEurobiomed
Founded in 2009 by regional stakeholders, EUROBIOMED is the Life Science cluster from Southern France. We gather more than 390 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients. Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centres, start-ups and industrial success stories. Some of Eurobiomed main assets are the number of people involved, but also the quality of the network and trust that is established between its members, which reinforces the interactions and facilitates collaborations.

Marseille
One of the best innovative hubs for biotech in Europe
The Aix-Marseille-Provence Metropolis and the Sud Provence-Alpes-Côte d’Azur Region are a dynamic hotbed for biotech and pharma innovations, providing unrivalled assets and cutting-edge resources. This is due in particular to its leading research and training centres, its incubators which boost R&D projects, Eurobiomed, the cluster which supports innovations’ development all along their development and its dedicated network including clusters, industries, SMEs and start-ups.

Life Science in Sud, Provence-Alpes-Côte d’Azur key numbers:
• $20 billion Life Sciences GDP in the region
• 2nd largest French region for clinical trials
• 170 laboratories in the health research
• 39,000 science students including 1,500 post-graduated with 8 universities and 4 teaching hospitals
• 41,000 life sciences entities
• 169,400 employees
THIS IS THE LAND OF INNOVATIVE THERAPIES!

A STRUCTURED, MULTI-SECTOR NETWORK
FOSTERING MARKET OPPORTUNITIES AND INNOVATION

Markets
- Medication
- Medical devices
- E-Health
- Diagnostics

Specializations
- Immunotherapy
- Oncology
- Infections diseases
- Neurology
- Medical device

41 000 public and private players
3.3B€ invested to date
#2 Région in France for patents and clinical trials

PRO VENCE-ALPES-CÔ TE D’AZUR
Conception-réalisation : Direction de la Communication et de la Marque de la Région Sud - Photo : gettyimages

Running out of battery?
Come to the on-site registration desk to borrow a powerbank!
STEERING COMMITTEE

PHARMA, BIOTECH

Damien Chopy
ROCHE

Adrian Carter
CORPORATE VICE PRESIDENT AND GLOBAL HEAD OF DISCOVERY RESEARCH COORDINATION, BOEHRINGER INGELHEIM

Sami Chtourdou
EXECUTIVE VICE PRESIDENT INNOVATION & SCIENTIFIC AFFAIRS, LFB

Florence Dal Degan
R&D INNOVATION SOURCING DIRECTOR, NOVO NORDISK

Guy Hélin
CEO, SYNGULON

Stephan Lensky
CHEF OPERATING AND CHEF BUSINESS OFFICE, EPIIMAB BIOTHERAPEUTICS

Sabrina Lesage
STRATEGIC ALLIANCES MANAGER, PZIFER

Sara Nunez-Garcia
SENIOR DIRECTOR, ROIANT SCIENCES

Marie-Ange N’Zoutani
DIRECTOR, EXTERNAL INNOVATION DRUG DISCOVERY, BUSINESS DEVELOPMENT & LICENSING, SANOFI

Frédéric Scaërou
SENIOR DIRECTOR, HEAD OF EXTERNAL INNOVATION EUROPE AND ASIA, IPSEN INNOVATION

Joachim Vogt
DIRECTOR, SEARCH AND EVALUATION, WESTERN EUROPE, ABBVIE

Nadine Weisslinger-Darmon
MEDICAL DIRECTOR SPECIALTY PRODUCTS, CLINICAL RESEARCH AND ACADEMIC ALLIANCES, ESK

ACADEMIA, TTOs

Hervé Ansanay
OPERATIONS DIRECTOR, SATT AXLR

Jürgen Bauer
DEPUTY MANAGING DIRECTOR, EMBLEM TECHNOLOGY TRANSFER

Garold Breit
CEO, BREIT IDEAS LLP

Jean-Luc Chagnaud
HEALTHCARE BUSINESS DEVELOPMENT MANAGER & INTELLECTUAL PROPERTY MANAGER, AQUITAINE SCIENCE TRANSPORT

Anthony Daccache
BUSINESS DEVELOPER, SATT NORD

Caroline Dreyer
PRESIDENT, SATT CONCUETS

Lilla Forkas
HEAD, OFFICE OF THE MANAGING DIRECTOR, RESEARCH COORDINATOR, MPHCONS, MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS

Esther Lange
INDUSTRY LIASON MANAGER, ASCENSION

INVESTORS

Anta Gkelou
ANALYST, SOFINNOVA PARTNERS

Frank Hensel
PRINCIPAL, HIGH-TECH GRÜNDERFONDS

Lotfi Yelles Chaouche
PARTNER, THEODORUS FUND

Jérôme Majoie
GENERAL MANAGER, FOUNDATION FOURNISSEURS MAJORIE

ASSOCIATIONS, CLUSTERS

Nicolas Carboni
PRESIDENT, RESEAU C.U.R.I.E.

Barbara Freischem
MANAGING DIRECTOR, EBE – EUROPEAN BIOPHARMACEUTICAL ENTERPRISES

Yohan Grosjean
COMMUNICATION OFFICER, APSSI – THE FRENCH ASSOCIATION OF OUTSOURCING AND INNOVATIVE COMPANIES

Jean-Louis Hunault
PRESIDENT, SIMV – THE FRENCH ASSOCIATION OF THE ANIMAL HEALTH INDUSTRY

Marco Pintore
GENERAL MANAGER, BIOVALLEY FRANCE

Emilie Royere
GENERAL MANAGER, EUROBIOMED

Etienne Vervaecke
GENERAL MANAGER, EURASANTE & CLUBSTER-NHL

TABLE OF CONTENTS

Organisers........................................................................... 4
Steering Committee.......................................................... 8
Sponsors..............................................................................11

BIOFIT AGENDA .................................................................... 16
HOSTED EVENTS AGENDA.......................................................... 18

ONE-TO-ONE MEETINGS
Partnering - Who will you meet?........................................... 20
Would-be CEO ...................................................................... 22

PITCH SESSIONS
Start-up Slams ...................................................................... 25
Collaborative and Licensing Opportunity Presentations ...... 28
Service Presentations............................................................ 30
Animal Health Collaborative Opportunity Presentations .... 32

CONFERENCES
PLENARY SESSION ..................................................................... 35
TRACK 1 | Best practices in academia-industry R&D collaborations ........................................................................ 36
TRACK 2 | Nurturing and licensing early-stage assets ............................................................................... 40
TRACK 3 | From pre-seed to Series A: Accessing early-stage investment ................................................................. 44
TRACK ANIMAL HEALTH HIGHLIGHTS .................................................. 48

HOSTED EVENTS
R&D Dating for Animal Health and Innovation .................. 50
Translational Neuroscience ................................................... 51
PIXR - Patient Innovation Xperience by Roche .................. 52
European Project Imode .......................................................... 53

EXHIBITION
Exhibitor List & Floor Plan .................................................... 56
Exhibitor Descriptions........................................................... 58
Sponsors.............................................................................. 84
Partners............................................................................. 86
Strategic **PARTNERSHIP** is at the heart of fulfilling Pfizer’s purpose as we work to translate advanced science and technologies into medicines and vaccines that significantly improve patients’ lives.

Visit the Pfizer partnering website to learn more about:
- Our Areas of Interest
- Our Partnering Leadership
- Our Process
- Partnering Highlights

www.pfizer.com/partners

---

**SPONSORS**

**GOLD SPONSORS**

**PFIZER**

www.pfizer.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

---

**SANOFI**

www.sanofi.com

Sharing expertise can fast-track innovation:

We are a global life sciences company committed to pursuing pioneering, life-changing treatments that address unmet healthcare challenges. Innovative collaborations are one of the fulfilling ways we meet those goals and create value for all involved. We are prioritizing our research efforts on delivering first- and best-in-class medicines - those with the potential to change people’s life.

Accelerate the development of your ideas and assets:

Tap into our deep expertise in developing, registering and bringing products to market. Together, we have the ability to go further faster and touch more people with the most innovative initiatives. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
GENFIT

www.genfit.com

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. Its most advanced drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial ("RESOLVE-IT") as a potential treatment for NASH, and GENFIT plans to initiate a Phase 3 clinical trial in PBC next year following its positive Phase 2 results. The company is also developing a new, non-invasive and easy-to-access blood-based in vitro diagnostic test to identify patients with NASH who may be appropriate candidates for drug therapy. Nasdaq and Euronext: GNFT.

MSD

www.msd.com

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide... and many of these advances were the result of partnerships. In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.

MSD ANIMAL HEALTH

www.msd-animal-health.com

MSD Animal Health is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets.
ALMIRALL
www.almirall.us
Almirall is a leading global pharmaceutical company, focused in medical dermatology and headquartered in Barcelona. Our strong commitment is to improve patients’ quality life while caring and listening to them. We work to offer innovative and differentiated medicines for skin conditions with high unmet need. We cover the whole of the drug value chain through an expert R&D organisation as well as key partnerships.

BAYER
www.bayer.fr
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

BOEHRINGER INGELHEIM
www.boehringer-ingelheim.com
Boehringer Ingelheim is a research-driven pharmaceutical company focused on improving the health and quality of life of patients. Working at the forefront of science and technology, our teams discover and develop innovative new medicines for the many diseases for which there are still no effective treatments. Independent and family-owned, we have the freedom to pursue our long-term vision so we can also begin the journeys of discovery that will help today’s children face a healthier future.

EVOTEC
www.evotec.com
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements.

IPSEN
www.ipsen.com
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US).

NOVO NORDISK
www.novonordisk.com
Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. We are committed to the discovery and development of innovative treatments for diabetes, obesity, haemophilia, NASH, atherosclerosis, heart failure, chronic kidney disease and we are seeking partnerships in all these indications. From molecule to market, our focus is on the patient. We are also committed to environmental and social responsibility.

ROCHE
www.roche.com
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and issue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to invest heavily in research and development with CHF 11 billion in 2018. Alongside the broad internal pipeline, external innovation has always been a critical component of the Roche research and development strategy.
### DAY ONE
**TUESDAY, DECEMBER 10TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>Name badge pickup &amp; welcome coffee</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Conferences and roundtable discussions</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Pitch sessions</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Partnering</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Welcome coffee</td>
</tr>
<tr>
<td>9:30 am</td>
<td>What are the outcomes of long-lasting commitment between universities and pharmaceutical companies?</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Networking break</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Plenary session: What is pharma looking for nowadays?</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Lunch</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Networking break</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>PLENARY SESSION: What is pharma looking for nowadays?</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>One-to-one meetings</td>
</tr>
</tbody>
</table>

### DAY TWO
**WEDNESDAY, DECEMBER 11TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>Conferences and roundtable discussions</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Pitch sessions</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Partnering</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Welcome coffee</td>
</tr>
<tr>
<td>9:30 am</td>
<td>How to prepare your package for a due diligence by a pharma player?</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Networking break</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Plenary session: What is pharma looking for nowadays?</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Lunch</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Networking break</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>PLENARY SESSION: What is pharma looking for nowadays?</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>One-to-one meetings</td>
</tr>
</tbody>
</table>

**TRACK 1**
- Best practices in academia-industry R&D collaborations

**TRACK 2**
- Nurturing and licensing early-stage assets

**TRACK 3**
- From pre-seed to Series A: Accessing early-stage investment

**ANIMAL HEALTH**
- Award Ceremony
### DAY ONE - TUESDAY, DECEMBER 10TH

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td>NAME BADGE PICKUP &amp; WELCOME COFFEE</td>
</tr>
<tr>
<td>9:00 am</td>
<td>R&amp;D dating for animal health and innovation</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Networking Break</td>
</tr>
<tr>
<td>11:00 am</td>
<td>LUNCH</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>R&amp;D dating for animal health and innovation</td>
</tr>
</tbody>
</table>

#### TRANSLATIONAL RESEARCH INFRASTRUCTURES
- 3D printing of personalised pharmaceutical solid dosage forms: promises and challenges
- Fabrication of 3D printing filaments for pharmaceutical and biomedical applications
- Engineering of pharmaceutical cocrystals and salts: State of the art industrial approaches
- Carbamazepin cocrystals revisited
- Nanofabrication techniques for enhanced drug delivery: from complex nanofibers to nanogels

#### NETWORKING BREAK
- Hot melt extruded polysaccharide blends for controlled drug delivery
- Electrospun formulations for colon targeting
- Investigation of complex molecular dynamics in multicomponent systems
- Stability and mobility of multicomponent pharmaceutical materials
- Starch matrix tablets for controlled drug delivery

#### LUNCH
- Stakes of training in translational neuroscience research – State-of-the-art and needs of academia and industry

### DAY TWO - WEDNESDAY, DECEMBER 11TH

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td>NAME BADGE PICKUP &amp; WELCOME COFFEE</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Inno'Area</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Animal Health Collaborative Opportunity Presentations</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Access and Financing Innovation</td>
</tr>
<tr>
<td>11:00 am</td>
<td>R&amp;D dating for animal health and innovation</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>e-Health</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Networking Break</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Lunch</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>R&amp;D dating for animal health and innovation</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Data</td>
</tr>
<tr>
<td>5:15 pm</td>
<td>Networking Break</td>
</tr>
</tbody>
</table>

#### INNOV' AREA
- Which promises to be delivered by high potential vaccines?
- How is AI based on wearables and sensors a major driver for the future of Animal Health and veterinary sciences?
- Advanced translational projects

#### LUNCH
- Stakes of training in translational neuroscience research – State-of-the-art and needs of academia and industry

#### SOCIAL INNOVATION
- Conclusions
48 hours to meet your future project partners, obtain funding and accelerate innovation

IDENTIFY today’s innovative technologies, collaborations and licensing opportunities
INITIATE discussions with potential partners, investors or clients
MEET the most qualified players in the Life Sciences field
DEVELOP new collaborations and partnerships

WHO WILL YOU MEET?

30% TTOs, Research institutions, Academics
20% Pharma & Diagnostic companies
20% Emerging Biotech companies
15% Preclinical CROs and CDMOs
10% Pre-seed, seed and Series A investors
5% Professional services, consulting and law firms

Changing patients’ lives together

“At Novo Nordisk, we believe that partnerships, based on long-term commitment and mutual interest, are key to fostering innovation. We work closely with universities and biotech companies worldwide to bring about innovation.”

Mads Krogsgaard Thomsen, Chief Science Officer of Novo Nordisk

Download the «Inova Event» app to receive your agenda updates
Organise your agenda | Request and manage meetings | Mobile messaging

Partnering at BioFIT is powered by
WOULD-BE CEO

Are you a bioentrepreneur seeking a project? Or do you have projects needing a CEO?

As talented CEOs are frequently sought-after by many actors of the biotech industry, this Would-be CEO session will bring together representatives of emerging start-ups, technology transfer offices, incubators and investing networks as well as CEOs and would-be CEOs to address this important issue.

Any bioentrepreneur looking for a project to get involved in is welcome to join the Would-be CEO session. Any incubator, tech transfer entity or scientific founder looking for an entrepreneur to lead their start-up projects is also welcome to join.

Bioentrepreneurs workshop:

- Panorama of European entrepreneurial training programmes
- How do I find the right co-founders? Which networks to activate? How do we find the risk takers and the co-entrepreneurs? Hear from savvy entrepreneurs and investors to receive feedback and best practices.

MOTERATOR:
Caroline Ramspacher
Innovation & Entrepreneurship Partner
Eurasanté

Luigi Costa
Entrepreneur In Residence
Sofinnova Partners

Matthieu Coutet
Managing Partner
Advent France Biotechnology

Networking cocktail:

This networking moment is the occasion to establish collaborations between future entrepreneurs and projects in need of CEOs.
The BioFIT pitch sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects, licensing opportunities and services in order to foster partnerships and business development in the Life Sciences field.

The winners will be awarded as the most innovative start-up, the most promising technology, the most innovative offer and the most innovative animal health project in Life Sciences during the Award Ceremony:

December 11th
From 4.00 pm
Innov’Area (Exhibition Hall)

START-UP SLAMS | AGENDA

The Start-up Slams are a great opportunity for young companies (and particularly start-ups seeking to raise a seed or a Series A financing round) to showcase their project in front of potential partners and investors.

Sponsored by:

December 10th | 2.00 pm - 4.15 pm | Innov’Area

INFECTION

MediSieve Ltd.
Sepsis | Blood-borne diseases | Platform therapeutic

LactaPure
Microbiome | Antibiotic resistance | Diabetes

CELL-THERAPY

BioFOR-Nerve
Biocompatible Organ Regeneration | Peripheral Nerve Regeneration | Nerve Hallow Tube/Connector

INNOVGEL
Hydrogels for 3D cell culture | Bio-inks for bioprinting | Tissue engineering and regenerative medicine

TRINCE
Transfection | Photoporation | Cell-based therapy

DenovoMATRIX GmbH
Coating | Stem cells | Chemically Defined
START-UP SLAMS | AGENDA

**December 10th | 2.00 pm - 3.30 pm | Innov’Area**

**CARDIO-METABOLIC**

**ENTEROSYS**
- Type 2 diabetes | Enteric nervous system | Gut-brain communication

**SKILLCELL**
- Diabetes | Urine test | Diagnostic

**Balmes Transplantation**
- Ischemia-reperfusion injury | Acute Kidney Injury | Chronic Kidney Disease

**WOUND-CARE**

**EvoBiotech**
- Biotech | Pharma | Medical device

**REGULAXIS**
- Gonarthrosis | Cartilage | Peptide

**ANIMAL HEALTH**

**AND Biopharma**
- Inhibitory action | DNA Self toxicity | Extracellular DNA (exDNA)

**PathoSense**
- Rapid diagnostic | Infectious diseases | Animal health

**Biocheck.ugent**
- Biosecurity | Farm | Coaching

**CANCER**

**Apmonia Therapeutics**
- Immuno-oncology | Drug peptides | Precision medicine

**SiBreaX AG**
- Drug development | Lung cancer | Drug Delivery

**Immune insight**
- Immuno-monitoring | Regulatory T cells (Tregs) | Predict and anticipate clinical trials or therapeutic treatments failure

**Nanoligent.SL**
- Metastasis | Oncology | Selective

**SideROS**
- Small molecules | Refractory/resistant cancer | Persister cancer cell

**ADCendo**
- Cancer | Antibody drug conjugate (ADC) | Established In vivo proof of concept

**Elphogene**
- Liquid biopsy | CeDNA | Colorectal cancer

**CNS**

**AgenT**
- Alzheimer’s | Machine Learning | Blood diagnosis

**MT-act**
- Tauopathy | Neurodegeneration | Optic nerve
The Collaborative and Licensing Opportunity Presentations are a great opportunity for TTOs, universities, research institutes and companies to showcase their early-stage technologies in front of potential partners, in order to entail a collaborative project and/or a licensing deal.

December 10th | 9.00 am - 10.30 am | Innov’Area

**DIAGNOSTIC**

**PEPperPRINT GmbH**
- Peptide | Neoepitopes | Biomarker

**University of Pardubice**
- Lipidomics | Mass spectrometry | Cancer screening

**Eötvös Loránd University, Faculty of Sciences, Budapest**
- Machine learning | Parkinson’s disease | Diagnosis

**CNS**

**Smoke Free Therapeutics**
- Smoking cessation | Immunotherapy | Natural extract

**Alcediag**
- Biomarkers | Epigenetics | Psychiatry

**CELL-THERAPY**

**Central European Institute of Technology (CEITEC), Brno University of Technology**
- Hybrid implant | Interbody fusion | Lumbar spine

**Institute of Experimental Medicine CAS & Bioinova**
- Cell therapy | Mesenchymal stem cells | Clinical grade solution

**INFECTION**

**SATT Linksium**
- Antibiotic | Bacterial resistance | Gram +

**Ai-biopharma**
- Hepatitis B virus | Liver targeting technology | Viral Capsid Assembly and Polymerase Inhibitors
The Service Presentations are a great opportunity for service providers and technology platforms with an innovative offer to showcase their offers in front of potential clients.

**December 11th | 10.30 am - 12.45 pm | Innov’Area**

### RESEARCH TOOLS

**DNAlytics**
- Multi-marker data analysis
- Predictive modelling
- From research to clinical routine

**Velabs therapeutics GmbH**
- Droplet based microfluidics
- HTS screening
- Functional antibodies on complex targets (like GPCRs)

**e-Zyvec**
- Gentic engineering
- Plasmid creation
- Co-design

**Ximbio**
- New and unique reagents
- Simplified Reagent Commercialisation and MTA licensing
- A fully funded internship programme

### DRUG DELIVERY TOOLS

**DIANA Biotechnologies**
- Ultrasensitive biomarker detection
- High-throughput screening
- Selectivity profiling

**NEUWAY Pharma GmbH**
- CNS Drug Delivery Platform
- Treatment of CNS-related diseases
- Partnering project with pharma companies

### PRECLINICAL TOOLS

**CYNBIOSE**
- Non Human Primate
- Immunotherapies
- Delayed-Type Hypersensitivity

**Repositive**
- Pre-clinical drug development
- Precision medicine
- Cancer therapy

**COMET Biobank**
- Tissue biobank
- Metabolic diseases
- Quality management system

### CLINICAL TOOLS

**Longeneration Limited**
- Clinical data
- Consent
- Life data economics

### PRODUCTION TOOLS

**DELPHARM**
- Hot Melt Extrusion (HME)
- Early formulation
- Poorly soluble drug

**Enantia SL**
- Cocrystals
- Purification
- Scalable

**Holodiag**
- X-ray powder diffraction
- Reference samples
- Polymorphic forms
ANIMAL HEALTH
COLLABORATIVE OPPORTUNITY
PRESENTATIONS | AGENDA

**EnvA - Veterinary National School of Alfort: EquiSym**
- Horse | Locomotion | Lamenesses | Biomechanics

**EnvA - Veterinary National School of Alfort**
- Therapeutic development | Broad-spectrum activity | Host-targeting agent

**ZOOPOLE development: CLOSTRICOX**
- Clostridium perfringens | Clostridium botulinum | Experimental models, chickens, feed

**INGULADOS**
- Bacteriocins | Synergistic antimicrobials | One Health

**University of Tours**
- Congenital neosporosis | Mucosa-nanoparticle | Vaccine

**SATT AxLR**
- Natural compound | Antibacterial | Aquaculture

December 11th | 9.00 am - 10.00 am | Innov’Area
WHAT IS PHARMA LOOKING FOR NOWADAYS?

A lot of pharma companies declare that they no longer want to be purely developers of drugs, and thus they progressively transition to become healthcare solution providers, trying to seek broader solutions to answer the patient needs, and changing the way they look at assets: What does it mean for the industry in terms of orientation of their scouting efforts, particularly for early-stage assets?

This session aims to understand pharma’s viewpoint, the consequences for the orientation of deals, the way it is going to influence the relationships with academia and biotech start-ups. How does this strategic intention modify the type and the nature of deals that pharma have with start-ups & academic institutions? How is it affecting early-stage licensing deals?
WHAT ARE THE OUTCOMES OF LONG-LASTING COMMITMENT BETWEEN UNIVERSITIES AND PHARMACEUTICAL COMPANIES?

To which needs do these numerous collaboration schemes answer? What are the specificities of these agreements in terms of management models and R&D means mutualisation. Are short-term reports and industry constraints coherent with multi-years academic agreements?

December 10th | 9.00 am - 10.30 am | STRASBOURG ROOM

Best practices in academia-industry R&D collaborations

MANAGING PRE-COMPETITIVE COLLABORATION IN LIFE SCIENCES: TESTIMONIALS ON OUTCOMES & LIMITS OF EUROPEAN CONSORTIA

Which research topics are considered good candidates for competitive consortia at the time of precision medicine? Are the current collaborative models (IMI, H2020...) adapted to the research needs? How to balance each party’s interests and define the domain of precompetitive research. How can IP problematics be managed?

December 10th | 2.00 pm - 3.00 pm | STRASBOURG ROOM
December 10th | 3.15 pm - 4.15 pm | LILLE ROOM

HOW CAN BIG DATA FUEL COLLABORATIONS BETWEEN INDUSTRY AND ACADEMIC INSTITUTIONS?

How can consolidating and mutualising data between industrial and academic players unlock the full potential of these partnerships? How can we make these data available to pharma and how can we make use of big data to fuel the pharma pipeline? Which collaboration models have emerged around big data? How is the central status of big data already entailing academia-industry collaborations?

MAGALI TOUROUDE-PEREIRA
CEO
Owkin

HANS CONSTANDT
CEO
Ontoforce

FRANCESCO RUESPISO
CBO
AcademicLabs

FREDERIC CAILLAUX
Deputy General manager Innovation
INPI

MODERATOR:
CORMAC SHERIDAN
Journalist
BioWorld

December 11th | 9.00 am - 10.00 am | STRASBOURG ROOM

WHAT ARE THE RECENT SUCCESSFUL INDUSTRY-ACADEMIA COLLABORATIONS IN ARTIFICIAL INTELLIGENCE?

What are the good examples of partnerships in this field? How have they proved to be fertile in innovation for the benefit of both parties?

MAGALI TOUROUDE-PEREIRA
CEO
YesMyPatent

MERIEM SEFTA
Head of Partnerships
Owkin

RAKESH UPPAL
Cardiac Surgeon
Barts and the London School of Medicine

MODERATOR:
NORA KHALDI
CSO
Nuritas

By 2050 the world’s population over 60 will have doubled to two billion, making age-related illness an even greater challenge for society. That’s why we’re seeking to help people stay healthier and more active in later life, by it through more targeted treatments for cancer and cardiovascular conditions, solutions for eye diseases, or ways to keep those with arthritis moving. Because life shouldn’t stop at 60 — not by any means. To find out how our innovations are helping to change lives for the better, visit our website : www.bayer.fr.
WHAT ARE THE MILESTONES TO BE REACHED FOR AN ACADEMIC ASSET?

How to evaluate an early-stage though promising asset? To what extent do experimented actors help the bio-entrepreneur to aim for a realistic maturation and validation roadmap? How do they help the managing team to understand value inflection points? How do the industry players (pharma, biotech, VC) handle this issue of granting of value to those assets? How could industrial players help academic institutions and TTOs avoid making mistakes at the very early development stages?

December 10th | 2.00 pm - 3.00 pm | LILLE ROOM

Gary Breit
CEO
Breit Ideas

Benjamin Soffer
Head of Strategic Corporate Partnerships
King’s College

Matthieu Coutet
Managing Partner
Advent France
Biotechnology

HOW TO PREPARE TO DUE DILIGENCE FROM A PHARMA PLAYER?

What are the key questions an academic project should address to ensure a valuable licensing deal in the view of pharmaceutical industries? How can a biotech company prepare for a due diligence by big pharma? Which areas are usually underestimated when preparing for a due diligence? What is an efficient due diligence plan? How to prepare an attractive asset to pharma and investors? What are the fundamentals of due diligence? What are the legal aspects to get prepared to?

December 11th | 9.00 am - 10.00 am | LILLE ROOM

Louise Jonshammar
Attorney at law
AWA

Klaus Dembowsky
CEO
amcure

Gary Breit
CEO
Breit Ideas

Benjamin Soffer
Head of Strategic Corporate Partnerships
King’s College

Matthieu Coutet
Managing Partner
Advent France
Biotechnology

Louise Jonshammar
Attorney at law
AWA

Klaus Dembowsky
CEO
amcure
WHICH NEW FORMS OF ACADEMIA-INDUSTRY PARTNERSHIPS TO BETTER MATURE ASSETS?

Numerous tools have been created in the last years, how do these early-stage financing vehicles work? On which bases do they ground funds allocation? What are the expectations of the limited partners? Who are the players involved in such investment tools, and what do they await from their involvement in such early-stage funding and investment tools?

Moderator:
Avishai Levy
Managing Partner
Agbiopro

Youness Karout
Researcher
University of Lille

Mark Slack
VP Academic Partnerships
Evotec

December 11th | 11.45 am - 12.45 pm | LILLE ROOM

WHAT TO ENSURE BEFORE THE CREATION OF A VIABLE SPINOUT OPPORTUNITY?

What does viable mean for TTOs, and do we have the same definition everywhere? On which grounds are TTOs advising to create a spin-off rather than out-licensing the IP or a contract-based R&D collaboration? Which are the benefits, limits, constraints and indication of the spin-out model? What are the key factors to create a well-conceived spin-off company, how to exploit and maximise the value creation?

Moderator:
Rafaela Kunz
Open Innovation Expert
INSEA Consulting

Jürgen Walkenhorst
Head of Technology Transfer
University of Vienna

Anna Białek Jaworska
Professor
University of Warsaw

December 11th | 4.00 pm - 5.30 pm | STRASBOURG ROOM

Working together for better health

We set the bar high for innovation. Motivated by patients, driven by science and inspired by our growing global community of partners, we are working hard to discover and develop the next generation of pioneering medicines. If you share our goal of researching and developing new medications to improve the health of people around the world, please join us in...

Working together for better health
Innovation @ Boehringer Ingelheim

For more information visit:
www.boehringer-ingelheim.com/partnering

PUB EVOTEC
WORKING WITH CORPORATE VENTURE FUNDS?
What are the benefits or constraints to go to a corporate venture tool? Is it better to go with a pharma player that wants to be a limited partner in existing funds rather than corporate ventures? As both have fundamentally different missions, what are the validating and limitation effects of working with a corporate VC? How to balance these two effects?

December 10th | 9.00 am - 10.30 am | LILLE ROOM

MODERATOR: Etienne Adriansen
Deputy Director
Healthcare Denmark

Cheryl Zimberlin
Principal
M Ventures

Joachim Vogt
Director, Search and Evaluation, Western Europe
AbbVie

WHICH FUNDING MODELS TO ACCELERATE ANTI-PARASITIC AND ANTI-INFECTIOUS INNOVATION?
Which funding to support new vaccines, drugs and treatment strategies in Africa? What is the role of philanthropic funding? How can foundations and governments form alliances to fund better R&D?

December 10th | 3.15 pm - 4.15 pm | STRASBOURG ROOM

MODERATOR: Isaac Haq
Analyst
ArchiMed Group

Santiago Ini
Director of Business Development
Technion Technology Transfer

Julie Brady
Business Development Manager
University of Dundee

Yann Ferrisse
Head of Business Development and Analysis
GARDP

Lionel Carnot
Partner
Earlybird Venture Capital

Joachim Vogt
Director, Search and Evaluation, Western Europe
AbbVie

From pre-seed to Series A: Accessing early-stage investment
CHALLENGING CONVENTIONAL WISDOM: IS EARLY-STAGE CAPITAL AS SATISFYINGLY AVAILABLE IN EUROPE AS WE LIKE TO BELIEVE?

How is it crucial to question the accepted common idea that Europe only lacks bigger funds for bigger roundtables and for more mature companies? Compared to European later-stage investment markets which are positively underfunded, it seems at first glance that the early-stage capital market is healthy and well-fuelled, but is it genuinely the case? Is the European early-stage capital market as rich in players and capital as it is said to be?

HOW TO SHAPE THE CORPORATE GOVERNANCE OF BIOTECH START-UPS AT THEIR VERY FIRST STEPS TO MAKE THEM SUCCESSFUL?

Beyond that the sole CEO appointment, how to cope with a pre-established governance from an academic spin-off? How can clashes of culture between researchers and industrials be beneficial and craft a balanced managing team? How are VCs expressing their demands and expectations and how are they filled up? To what extent is leaning on international strategic and scientific committees as soon as they are born a recipe of success?

WHAT’S HOT, WHAT’S NOT? WHAT’S ON THE INVESTORS’ WISHLIST FOR 2020?

How do the deals and lessons-learned from 2019 investment let us peak at what can be expected for 2020? What are the tips for success for next year? Which therapeutic area will gain or reinforce interest from the VCs? How can you make sure that your business will be on VC’s radar?

WE LISTEN TO AND LEARN FROM PATIENTS EVERY DAY...

We are dedicated to improving patients’ lives through innovative medicines in Oncology, Neuroscience and Rare Diseases. Because patients can’t wait.

www.ipsen.com
HOW IS AI BASED ON WEARABLES AND SENSORS A MAJOR DRIVER FOR THE FUTURE OF ANIMAL HEALTH AND VETERINARY SCIENCES?

What is the understanding of AI technologies and machine learning within the animal health industry? With the huge amount of data provided by wearables and sensors, how can data be utterly exploited? How is the future lying in real-time predictive analysis? How is AI bringing changes in business models through automated veterinary diagnostic tools?

December 10th | 4.30 pm - 6.00 pm | STRASBOURG ROOM

MODERATOR:
Klaus Hellmann  
CEO  
Klifovet AG

Scott Brown  
HEAD of Research & Development  
Zoetis

Pauline Ezanno  
Researcher  
French National Institute for Agronomic Research

Timothée Audouin  
Animal e-Health consultant

WHICH PROMISES TO BE DELIVERED BY HIGH POTENTIAL VACCINES?

How can international and multidisciplinary approaches like the SAPHIR European project help develop innovative vaccination strategies? How are these kinds of projects integrating vaccination in a global health management system? What are the outcomes and expected developments in terms of vaccines production of these multi-million international project? How are these vaccines strengthening the profitability of food systems?

December 11th | 2.00 pm - 3.30 pm | STRASBOURG ROOM

Jean-Pascal Marc  
Corporate Product Innovation Director  
Virbac

Jean-Christophe Audonnet  
Senior Director, International R&D Governance, Coordinator of ZAPI IMI Project  
Boehringer Ingelheim

Sabine Riffault  
Director of research  
French National Institute for Agricultural Research

Belen Barreiro  
General Director  
INGENASA

Timothée Audouin  
Animal e-Health consultant

Scott Brown  
HEAD of Research & Development  
Zoetis

Pauline Ezanno  
Researcher  
French National Institute for Agronomic Research
Translational Neuroscience research helps to provide R&D continuum from discovery to clinical phases by gathering multidisciplinary expertise, state-of-the-art technology platforms and innovative methodologies.

This event highlights innovative translational research for neurodegenerative diseases with a market focus. Thus, academia-industry relationships will be developed not only from the science and technology point of view but also through training / education required to constantly remain at the forefront of innovation. This new edition gathers experts in neurodegenerative diseases and fosters interactions between researchers, clinicians, biotech and pharmaceutical companies.

**THE PROGRAMME IN A NUTSHELL**

**Session I: Translational Research Infrastructures**

- **9.00 - 10.30 am**
  - **DHUNE** – Olivier Blin (DHUNE director)
  - **NEURATRIS** – Philippe Hantraye (MIRCen (CEA) and NeurATRIS)
  - **Brain diseases: Advances, challenges and obstacles** – Catherine Lubetzki (Pitié-Salpêtrière Hospital)
  - **Round table I**: Role of public and industry actors in neuroscience translational research – What mechanisms and resources to support translation up to phase 2?
    - **Moderator**: Toni Andreu – CSO EATRIS-ERIC
    - **Panel**: Angel Cedazo-Miguez (Sanofi), Aline Jourdain (BPI), Michel Khrestchatisky (Vect-Horus), Emmanuel Le Bouder (Eurobiomed), Catherine Lubetzki (Pitié-Salpêtrière Hospital), Bruno Marroni (Protisvalor)

**Round table II**

- **11.00 am - 12.30 pm**
  - Role of public and industry actors in neuroscience translational research – State-of-the-art and needs of academia and industry
  - Introduction of a market study on Translational neuroscience training by Vincent Gleize (Erdyn)
    - **Moderator**: François Féron – NeuroSchool Director
    - **Panel**: Olivier Blin (DHUNE), Marc Dhenain (NeurATRIS and MIRCen), Corinne Grenier (KEDGE Business School), Rosan Vegter (EATRIS-ERIC)

**Advanced translational projects**

- **Lionel Lamothe (Exostim)**
- **Mathieu Charveriat (Theranexus)**
- **Michel Khrestchatisky (Vect-Horus)**
- **Sylvie Claeyisen (Montpellier University)**
- **Philippe Verwaerde (A1zProtect)**

**Organised by**

simv.org

Contact: secretariat@simv.org

---

**R&D DATING FOR ANIMAL HEALTH AND INNOVATION**

BioFIT 2019 hosts the 5th edition of the “R&D dating for Animal Health and Innovation” business convention, at the French association for the animal healthcare industry (SIMV)’s initiative, on December 10th and 11th, 2019 in Marseille.

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).

By enabling face-to-face encounters, the event enhances the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

Animal health-related roundtable discussions during BioFIT:

- How is AI based on wearables and sensors a major driver for the future of Animal Health and veterinary sciences?
- Which promises to be delivered by high potential vaccines?

**Organised by**

simv.org

Contact: secretariat@simv.org
Roche is organising **PIXR – Patient Innovation Xperience** during BioFIT 2019. The day is dedicated to conferences, round-tables and pitches around Health Innovation. 4 themes are discussed:

- Access and Financing Innovation
- Data
- E-Health
- Social Innovation

**PROGRAMME:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00 - 9.15 am</td>
<td>Introduction by: Mr Renaud Muselier, President of the Sud Provence-Alpes-Côte d’Azur Region</td>
</tr>
<tr>
<td>9.30 - 10.30 am</td>
<td>Access and Financing Innovation</td>
</tr>
<tr>
<td>10.30 - 11.00 am</td>
<td>Networking break</td>
</tr>
<tr>
<td>11.00 am - 12.30 pm</td>
<td>E-Health</td>
</tr>
<tr>
<td>12.30 - 2.00 pm</td>
<td>Lunch</td>
</tr>
<tr>
<td>2.00 - 3.30 pm</td>
<td>Data</td>
</tr>
<tr>
<td>3.30 - 4.00 pm</td>
<td>Networking break</td>
</tr>
<tr>
<td>4.00 - 5.15 pm</td>
<td>Social Innovation</td>
</tr>
<tr>
<td>5.15 - 6.00 pm</td>
<td>Conclusion by: Mr André Comte-Sponville, Writer, Professor, Philosopher, author of the famous “Petit traité de grandes vertus” Mr Jean-François Brochard, President, Roche France</td>
</tr>
</tbody>
</table>

**EUROPEAN PROJECT IMODE**

*IMODE is organising its fourth annual convention during BioFIT with a morning of conferences and one-to-one meetings during the afternoon.*

**PROGRAMME:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00 - 9.25 am</td>
<td>Dr Sheng Qi, University of East Anglia &quot;3D printing of personalised pharmaceutical solid dosage form: promises and challenges&quot;</td>
</tr>
<tr>
<td>9.25 - 9.35 am</td>
<td>Roxanne Khalaj, PhD, University of Greenwich &quot;Fabrication of 3D printing filaments for pharmaceutical and biomedical applications&quot;</td>
</tr>
<tr>
<td>9.35 - 10.00 am</td>
<td>Dr Steven Ross, University of Greenwich &quot;Engineering of pharmaceutical cocrystals and salts: State of the art industrial approaches&quot;</td>
</tr>
<tr>
<td>10.00 - 10.10 am</td>
<td>Luisa Roca Paixao, PhD, University of Lille &quot;Carbamazepin cocrystals revisited&quot;</td>
</tr>
<tr>
<td>10.10 - 10.35 am</td>
<td>Dr Duncan Craig, University College London &quot;Nanofabrication techniques for enhanced drug delivery: from complex nanofibers to nanogels&quot;</td>
</tr>
<tr>
<td>10.35 - 11.00 am</td>
<td>Break</td>
</tr>
<tr>
<td>11.00 - 11.25 am</td>
<td>Dr. Youness Karrou, University of Lille &quot;Hot melt extruded polysaccharide blends for controlled drug delivery&quot;</td>
</tr>
<tr>
<td>11.25 - 11.35 am</td>
<td>Zuzana Hlaskova, PhD, University of East Anglia &quot;Electrospun oral formulations for colon targeting&quot;</td>
</tr>
<tr>
<td>11.35 - 12.00 am</td>
<td>Natalia T. Correia, University of Lille &quot;Investigation of complex molecular dynamics in multi-component systems&quot;</td>
</tr>
<tr>
<td>12.00 - 12.10 pm</td>
<td>Jeanne-Annick Bama, PhD, University of Lille &quot;Stability and mobility of multicomponent pharmaceutical materials&quot;</td>
</tr>
<tr>
<td>12.10 - 12.35 pm</td>
<td>Nicolas Descamps, Roquette &quot;Starch matrix tablets for controlled drug delivery&quot;</td>
</tr>
</tbody>
</table>

**IMODE partners:**

**Contact:** slebrun@clubster-nsl.com  
**project-imode.eu**

IMODE is a collaborative research project for multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices that are loaded with bioactive molecules. Started in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Regional Development Fund (ERDF).

The project’s overall objective is to bring together the specific transdisciplinary skills and experiences of partners (academic research groups, development agencies, SMEs) in order to provide the 2 Seas Area with strategic advantages for innovative pharmaceutical and medical applications. The IMODE project is motivated by an unmet need to develop solutions to addressing societal challenges to improve healthcare and provide novel and effective medication for various cardiovascular or gastro-intestinal conditions that lack or have inadequate treatment, all while keeping medical costs low.
BIO party

DECEMBER 10TH
FROM 6.30 PM
ORANGE VELODROME STADIUM
SALON DES LÉGENDES

NETWORKING | MUSIC | DANCING | COCKTAILS
PHOTOBOOTH | TABLE FOOTBALL & BOULES

PARTNERING TO ADVANCE GLOBAL HEALTH

www.sanofi.com
Global_Partnering@sanofi.com
54 Rue La Boëtie
75008 Paris
EXHIBITION LIST & FLOOR PLAN
EXHIBITORS

3M
www.3m.com/3M/en_US/bioprocessing-us
3M Separation and Purification Sciences Division provides cutting edge separation and purification technology and products for biopharmaceutical companies involved in production of recombinant proteins, plasma fractionation products, vaccines and small molecule drugs. Using 3M’s innovative material science platforms, we help companies optimize their processes, improve product safety and increase manufacturing efficiencies, thereby, improving lives everywhere as a trusted supplier of purification.

AMYLGEN
www.amylgen.fr
AMYLGEN is a privately owned contract research organization (CRO) offering a unique combination of validated in vivo models and a full range of biochemical and morphological testing allowing fast and predictive screening of the effects of drugs and nutraceuticals on brain health.

ANTAPODIA THERAPEUTICS;
KUPFFER BIOATHERAPEUTICS
www.antapodia.com
Antapodia Therapeutics and Kupffer Biotherapeutics are subsidiaries of Stempodia Corporation, a science-driven biopharmaceutical startup providing breakthrough solutions for advanced and metastatic cancers. The company’s first-in-class invadopodia-targeted gene therapies have shown dramatic anti-metastasis efficacy and can be quickly moved to clinical trials. The company’s Kupffer technology solves multiple obstacles to develop first-in-class immune-cell therapies for desmoplastic GI cancers.

ATLANPOLE BIOTHÉRAPIES
www.atlanpolebiotherapies.com
Atlanpole Biotherapies is a competitiveness cluster involved in the medicine of tomorrow. It is focused for the development of new therapies, immunotherapy, regenerative medicine and radiopharmaceuticals, on the bio-medicine value chain from target discovery to clinical evaluation, completed by digital and nutrition approach. The projects of our network of 230 members, both academic and industrial, show the excellence of our expertise in personalized medicine.

ADMESCOPE LTD.
www.admescope.com
Admescope provides the pharmaceutical, biotechnology and veterinary industry tailor made ADMET-Tox services. Our service offering covers research services for peptides, biologics and small molecules and is widely spread over the whole ADMET-Tox area. The right assays are available, whether in the discovery or lead optimisation phase. The level of data interpretation can be customized according to customer preferences. Currently Admescope serves customers in 27 countries on four continents.

AGRO-BIO ANTIBODIES
www.agro-bio.com
Agro-Bio provides Antibody services for life sciences industries. Customized anti-idiotypic and anti-drug antibodies. Specific anti-HCP antibodies and HCP ELISA kits (coverage 2D). Biacoer platform, affinity and kinetics, CQA: active concentration, Fc receptor binding... Identify antibody-binding sites on an antigen (Epitope Mapping). For your diagnostics kits with our customized polyclonal/monoclonal antibody development and our large-scale antibody production.

AGUITAINE SCIENCE TRANSFERT
www.innovations-aquitaine.com
Aquitaine Science Transfer is the Technology Transfer Office for the south west of France, covering 5500 researchers and 135 laboratories. We represent the regional academic research labs: Bordeaux University, INSEER, CNRS, Pau University, Bordeaux Polytechnic Institute... Since our creation in July 2012, we have signed 48 license agreements, patented 285 technologies and created 17 startups. Health, wellness and medical devices represent a key business in which our company is highly involved.

AEPODIA
www.aepodia.com
Aepodia is a solution provider specialised in the early development of drugs and medical devices up to clinical proof-of-concept (from preclinical to Phase 2). Aepodia offers expertise and innovative approaches to its partners to optimise the clinical development programmes of products as well as the management and operational execution of clinical studies carried out in multiple countries. With offices in Belgium and France, Aepodia is a recognised partner for pharma and biotech companies.

ALCEDIA
www.alcedia-alcen.com
Created in 2013, ALCEDIA is a personalized medicine company specializing in the development of diagnostics tests and clinical biomarkers with a primary focus on mental health and «precision psychiatry». ALCEDIA has developed different signatures of blood biomarkers based on analysis of RNA editing, an epigenetic mechanism, combined with Artificial Intelligence algorithms. The first product of ALCEDIA is Edit-B, a blood test to differentiate bipolar depression from unipolar depression.

AXLR
www.axlr.com
AxLR is a technology transfer acceleration company. Our specialty is helping innovative projects derived from academic research reach maturity and commercialization. We work with the main public-sector research laboratories in France’s Mediterranean area in Occitanie, one of the most dynamic locations in Europe, with over 200 laboratories and some 12,000 researchers.

BACHEM AG
www.bachem.com
Bachem is specialized in the process development and manufacturing of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach. Bachem shows total commitment to quality, innovation and partnership. Bachem. Pioneering Partner for Peptides.
**BIC - BIOMARKER COMMERCIALIZATION**

www.biomarker.nu  STAND G10

The BIC, Biomarker Commercialisation, is a project developing tools to support researchers, TTOs and small companies for a more successful commercialisation of biomarkers inventions. The final tools will be a BIC Master Tool, from discovery to market launch, a Best Practices Handbook based on experiences from TTO in the field, a screening and selection guide for TTOs and a regulatory guideline. Tools will be available in summer 2020. BIC is granted by the Interreg programme Baltic Sea Region.

**BIOGENOUEST**

www.biogenouest.org  STAND D23

Biogenoquest provide state-of-the-art research facilities to the scientific community in western France. We combine expertise, capability and equipment through a network of technology core facilities. Our team all strive to develop state-of-the-art technologies platforms drawing on a coordinated approach. Our network brings together 35 technology core facilities that deliver hands-on solutions for labs and businesses across: genomics, proteomics, functional exploration, bioimaging structural and metabolic analysis, bioinformatics.

**BLOCK-T**

www.block-t.com  STAND I20/1

BLOCK-T is a startup incubated at EURASANTÉ since October 2018, whose main activity is the development of preclinical traceability software. Based on our preclinical research experience, BLOCK-T aims to help improve the quality of preclinical laboratory experiments. Our innovation lies in the creation of TracePic, the first Blockchain traceability software dedicated to laboratories, and developed to improve the tracking and traceability of experimental data.

**BIOALTERNATIVES**

www.bioalternatives.com  STAND 21/5

Bioalternatives offers various in silico, in vitro and ex vivo complementary services that are suitable for drug discovery (screening, profiling, safety) and can also provide you with assays for claim substantiation (proof of concept, repositioning, benchmarking). Our main fields of study are healthy and/or pathological skin (e.g. psoriasis, atopic dermatitis, wound healing, fibrosis, etc.), immune-inflammation and more generally pharmacology (signaling, stress, ageing).

**BIOREA**

www.biorea.fr  STAND C13

Do you need taylor-made biomass of your strain (bacteria, yeast, microalgae)? Do you need taylor-made biomass for your DSP projects? Bioreá, subsidiary of Agrifood, relies on its patented fermentation technology for:
- Taylor-made biomass with complete scale-up from lab scale to industrial volumes
- R&D service to adapt your strain & medium to our technology
Should you want to run more R&D trials in your lab, you can also «Cultivate-it-yourself» with our bioreactor equipment.

**BRAND INSTITUTE**

www.brandinstitute.com  STAND C14

Brand Institute was created on this principle: provide the highest quality name development services, produced and presented by the most experienced professionals, in a timely manner, and at a competitive price. OUR MISSION: To provide best-in-class strategy, name development, trademark screening, market/safety research and visual identity service to our valued, global clientele, delivered by 250+ of the most experienced and forward-thinking branding professionals in our industry.

**CARNOT FRANCE FUTUR ELEVAGE**

www.francefuturelevage.com  STAND G20

Carnot France Futur Elevage is a French public research network that provides R&D competences to livestock farming sector businesses, including health, nutrition and breeding systems. It brings together actors from agro-veterinary research from INRA and its academic partners with an international visibility and three Agricultural Technical Institutes leaders in the breeding services.

**BIORN**

www.biorn.org  STAND E24

BioRN is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany’s strongest biotech hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders. One of BioRN’s tools to achieve translation of research is HAEP, a scouting service for a tailored matching between innovation seekers and innovators.

**CEMIPAI**

www.cemipai.fr  STAND E23-16

The CEMIPAI is a CNRS-Montpellier University laboratory made up of one of the largest level 3 containment facility in France. Our services support both basic and translational biomedical research on human pathogens for companies and academics. A screening service is available for semi-automated drug or antibody screening against a growing number of viruses. State-of-the-art BLS3 microscopies offer cutting-edge technology for the detection, quantification and analysis of viruses and bacteria.

**CENTRE FOR TRANSFER OF BIO MEDICAL TECHNOLOGIES**


Centre for Transfer of Biomedical Technologies was founded in 2012 at the University Hospital Hradec Králové, Czech Republic as a joint commercialization office for researchers of University Hospital Hradec Králové, University of Hradec Králové and Faculty of Military-Health Sciences, University of Defense. The mission of CTBT is to protect the intellectual property of all participating institutions, and to transfer the outcomes of R&D to the market and to negotiate and contract research.
CER GROUPE  www.cergroupe.be  STAND I10

CER Groupe is a Belgian Registered Research Center established 40 years ago providing services, products and research in veterinarian, biotech and biomedical areas. Our activities are focused on preclinical, analytical and biomanufacturing fields. We offer fully customized and integrated solutions to our partners, from start-up, spin-offs and early-stage companies to big pharma. These services are performed according to the most appropriate quality standards, from R&D up to GLP and GMP.

CLUBSTER NHL  www.nhl-cluster.com  STAND I20

Clubster NHL – Nutrition, Health, Longevity – is a French competitiveness cluster federating 450 members in the Nutrition, biotechnology and health sectors. We foster collaboration between academia, private companies (start-up, SMEs and large companies), clinicians and final users. Our aim is to help our members to design, develop and finance their innovative products and processes. The activity encompasses the ONE HEALTH concept, close relation between human, animal and plant health.

CILCARE  www.cilcare.com  STAND D21/6

CILcare is the world’s leading CRO offering preclinical services and consultancy in ear disorders. Based in Montpellier, Boston, and Paris, CILcare supports pharma, medtech, nutraceutical, and veterinary industries to assess efficacy and safety of drugs, cell and gene-based therapies, medical devices on hearing loss, tinnitus, and otic disorders.

CRYOPDP AN AIR LIQUIDE COMPANY  www.cryopdp.com  STAND C10

For over 25 years, CRYOPDP, an Air Liquide subsidiary, advise his lifescience industry customers for the transport of their temperature and time sensitive products. CRYOPDP design tailor-made solutions to secure the logistic of clinical trials and R&D samples, thanks to a team of logistic experts and all the entities strategically located around the world.

CILIO  www.ciloa.fr  STAND E23-14 / E23-15

CILIO’S CUSTOMIZED EXOSOMES FOR INNOVATIVE THERAPEUTICS. CILIO is the Pioneer exosome Company with the highest R&D experience on recombinant exosomes. CILIO innovative platform allows to develop Therapeutic Vectors, Therapeutic Antibodies and Adjuvant- & Virus-Free Vaccines. CILIO customizes exosomes in vivo to contain i) fully native membrane protein complexes (GPCRs, Kinase Rec., Transporters, Ion Channels, Viral Antigens, ...) embedded in their membrane and ii) any proteins inside their cytosol.

CYNBIOSE  www.cynbiose.com  STAND D21/3

Cynbiose is a preclinical CRO specialized in nonhuman primate [NHP] translational models for biomedical research. We provide preclinical services ranging from PK/PD exploratory studies to pharmacological PoC studies in various physiopathological diseases models (Infectious and respiratory diseases, CNS, Rheumatology, Cardiovascular diseases, ...). We also provide different proprietary technical platforms and the Immunoload platform for the assessment of immunotherapies and vaccines.

CZECHINVEST  www.czechinvest.org  STAND H23

CzechInvest, the Investment and Business Development agency of the Ministry of Industry and Trade, works with businesses based in the Czech Republic to support their development and encourages foreign companies to look at the Czech Republic as their partner of choice. Our consultancy services are provided free of charge and cover among others market intelligence including technology scouting as well as strategic and R&D collaboration in strategic sectors including biotechnology, pharmaceuticals.

DRUGABILIS  www.drugabilis.com  STAND D21/10

DRUGABILIS is an established CRO specialized in pharmaceutical drugability of R&D compounds, including cytotoxic drugs. Our expertise includes API Solid Form Optimization (salts, polymorphs, cocrystals) & Early Formulation, ranging from animal formulation (efficacy, PK, Tox) to early clinical formulation feasibility assessment (oral low soluble, injectable, ocular, dermal, vaginal ...). Our recent relocation to new facilities allowed us increasing our capacities for new projects and clients.

ER2I INGÉNIERIE  www.er2i.eu  STAND F23

Engineering and general contractor – designer and builder of buildings and complex processes. ER2I engineering is an engineering and contracting company based in Grenoble, Lyon and Paris, which specialize in highs standards buildings and structures. We are recognized on both the national and international levels, as a main actor of the construction sector for specific and innovative markets. We are specialized in pharmaceutical and cosmetical industries, medtech and research laboratories.
Erdyn is a pure player of innovation. Erdyn is a leader consulting company specialized in innovation. We support our clients from strategies set up to their operational implementation to sustain growth and competitiveness through innovation. We offer support for:
- Set up and management of collaborative projects
- Innovation marketing and business development
- Technological and scientific states of the art
- Technology/opportunity scouting

EUROBIOMED is the catalyst of the health sector in Southern France. EUROBIOMED leads territorial initiatives, provides resources and offers solutions for businesses and research organizations. EUROBIOMED helps them to innovate, finance, develop and achieve their strategic and business objectives to ultimately improve life through innovations in health. EUROBIOMED tops European rankings in all stages of innovation. Together, the + 390 EUROBIOMED members are a driving force in regional development (with 290 projects, representing +1 billion Euros).

Eurasanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurasanté provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurasante Bio-business Park, which already hosts 8 hospitals, 4 universities, 8 specialised schools and more than 170 companies. It benefits from an exceptional location at the heart of Europe.

We provide an integrated service for design and production of tailor-made DNA vectors. We enable ambitious projects by generating powerful molecular tools in shorter times. We are R&D boosters, we help progress makers! We contribute to the biotechnologies that will make the century greener, safer and more sustainable.

Get-IT (Genomics and Transcriptomics-INRA TRANSFERT) offers a range of services based on innovations from INRA (Get and INRA-TRANSAF) platforms that meet the expectations and needs of companies in genomic and transcriptomic applications, clinical studies or pilot projects. Our service allows you to offer multi-technology approaches to answer some biological questions of private companies, including sequencing strategy advices (NovaSeq, MiSeq, ONT…), DNA/RNA extraction, data production and bioinformatics/biostatistics analyses. Get-IT offers a complete range of services to reach the needs of companies in the healthcare, pharmaceutical / cosmetics, biotechnology, agri-food, agricultural, animal and environmental sectors.

Ezyn is a pure player of innovation. Ezyn is a leader consulting company specialized in innovation. We support our clients from strategies set up to their operational implementation to sustain growth and competitiveness through innovation. We offer support for:
- Set up and management of collaborative projects
- Innovation marketing and business development
- Technological and scientific states of the art
- Technology/opportunity scouting

Eurasanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurasanté provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurasante Bio-business Park, which already hosts 8 hospitals, 4 universities, 8 specialised schools and more than 170 companies. It benefits from an exceptional location at the heart of Europe.

EUROBIOMED is the catalyst of the health sector in Southern France. EUROBIOMED leads territorial initiatives, provides resources and offers solutions for businesses and research organizations. EUROBIOMED helps them to innovate, finance, develop and achieve their strategic and business objectives to ultimately improve life through innovations in health. EUROBIOMED tops European rankings in all stages of innovation. Together, the + 390 EUROBIOMED members are a driving force in regional development (with 290 projects, representing +1 billion Euros).

Eurasanté is an exceptional location at the heart of Europe.

EUROFINS CDMO is a leader consulting company specialized in innovation. We support our clients from strategies set up to their operational implementation to sustain growth and competitiveness through innovation. We offer support for:
- Set up and management of collaborative projects
- Innovation marketing and business development
- Technological and scientific states of the art
- Technology/opportunity scouting

EUROFINS CDMO is an exception leader consulting company specialized in innovation. We support our clients from strategies set up to their operational implementation to sustain growth and competitiveness through innovation. We offer support for:
- Set up and management of collaborative projects
- Innovation marketing and business development
- Technological and scientific states of the art
- Technology/opportunity scouting

EUROFINS CDMO is a leader consulting company specialized in innovation. We support our clients from strategies set up to their operational implementation to sustain growth and competitiveness through innovation. We offer support for:
- Set up and management of collaborative projects
- Innovation marketing and business development
- Technological and scientific states of the art
- Technology/opportunity scouting

EUROFINS CDMO is a leader consulting company specialized in innovation. We support our clients from strategies set up to their operational implementation to sustain growth and competitiveness through innovation. We offer support for:
- Set up and management of collaborative projects
- Innovation marketing and business development
- Technological and scientific states of the art
- Technology/opportunity scouting
HALIODX

HaloDx is an immuno-oncology diagnostic company providing oncologists with diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology. HaloDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. HaloDx has an experienced team of more than 165 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US.

www.haliodx.com

STAND D24

HOLODIAG

Holodiag is your expert CRO dedicated to API solid state, crystallization process and preformulation. Our services include:
- Solid state screenings (polymorph, salt, co-crystal);
- Solid form studies (solubility, dissolution, stability);
- Crystallization process (solid form control, yield/purity, particle engineering, filtration/drying);
- Method development (XRPD, DSC, TGA, DVS, PSD and more).

www.holodiag.com

STAND J14

IMMUNE INSIGHT

Immune insight is a CRO which carries ex-vivo and in-vivo preclinical assessment of new active molecules on the immune system in the fields of Cancer, Autoimmune and Inflammatory diseases. Immune Insight has a strong expertise in Treg full analysis but provides also a full range of services including phenotypic, metabolic, functional, recruitment and conversion analysis of several other human immune cells (monocytes, NK, macrophages, B and T cells, Neutrophils...).

www.immune-insight.com

STAND I20/3

HALIODX

www.haliodx.com

STAND D24

High Force Research Ltd

HFR is a premier CRO/CDMO company, creating specialist materials to GMP standards and developing synthetic manufacturing processes. With extensive experience of applied chemistry across numerous industry sectors and academia, our materials are used in wide range applications from Pharmaceuticals to Diagnostics, and Smart Materials to Organic Electronics. We operate a hybrid business model combining CRO/CDMO with collaborative research programmes aimed at the development of value added products.

www.highforceresearch.com

STAND C12

ID2SANTÉ

ID2Santé is a technology innovation centre operating in the Bretagne region (Western France). It is also the regional representative of the Atlanpole Biotherapies competitiveness cluster. It is in close contact with regional researchers and companies from the health sector and helps forge partnerships to support R&D projects and to develop innovative health products.

www.id2sante.fr

STAND E13

INNOVA SOFTWARE

Inova Software accelerates biopharma partnering. Our cloud-based solutions help life science companies manage their opportunities more efficiently. They find all their partnering information in one place, track their deals and alliances easily, and report on their pipeline and activities in seconds. Over 130 life science companies, including 50% of the top 50 pharma companies and many midsize pharma, biotechs and research institutes, already use Inova.

www.inova-software.com

STAND D13

INSERM TRANSFERT

As a private subsidiary of the French National Institute of the Health and Medical Research (Inserm), Insren Transfert manages economic and societal value creation and the transfer of knowledge from Inserm research laboratories to companies, contributing to promote human health innovation and long-term technology transfers in line with international best practices.

www.technology-offers.inserm-transfert.com

STAND H20

HPC - COES

The HPC Centres of Excellence (CoEs) are EU funded projects supporting the uptake of simulation and numerical modellings in industry in various domains of life sciences. The project ComBioMed is focussed on tools and support for cardiovascular and neuro-musculoskeletal simulation & molecular medicine. The POP project provides performance optimisation & productivity services for academic and industrial codes. These projects offer professional services delivered by the research community itself.

www.focus-coe.eu

STAND D12

IMODE

The IMODE project is motivated by an unmet need for developing solutions to address societal challenges for improved healthcare, novel and effective medicines for various cardiovascular or digestive diseases, which have inadequate or lack of treatment while maintaining low medical costs. The IMODE project is divided in two main scientific workpackages: -Innovative pharmaceutical formulations and technologies; -Innovative medical devices with improved therapeutic activity based on co-drugs.

www.project-imode.eu

STAND E21

INSTITUT CARNOT CALYM

The CALYM Carnot Institute brings together 15 research teams specialized in lymphoma, First blood cancer. This academic consortium, without international equivalent, aims at accelerating innovation and its transfer in the lymphoma treatment and diagnosis through a unique R&D offering: from the identification of new biological targets to registration clinical trials.

www.calym.org

STAND H24

HCS PHARMA

HCS Pharma is a biotech company focused on preclinical in vitro studies, specialized in high content analysis (HCA) and high content screening (HCS). We evaluate the efficacy and safety of your molecules (drug, ingredient, or cosmetic actives) on innovative 2D and 3D cellular models. HCS Pharma owns and sells BIOMIMESYS® technology, a reproducible and physiological surrogate extracellular matrix for 3D cell culture.

www.hcs-pharma.com

STAND I20/2

HPC - COES

The HPC Centres of Excellence (CoEs) are EU funded projects supporting the uptake of simulation and numerical modellings in industry in various domains of life sciences. The project ComBioMed is focussed on tools and support for cardiovascular and neuro-musculoskeletal simulation & molecular medicine. The POP project provides performance optimisation & productivity services for academic and industrial codes. These projects offer professional services delivered by the research community itself.

www.focus-coe.eu

STAND D12

IMODE

The IMODE project is motivated by an unmet need for developing solutions to address societal challenges for improved healthcare, novel and effective medicines for various cardiovascular or digestive diseases, which have inadequate or lack of treatment while maintaining low medical costs. The IMODE project is divided in two main scientific workpackages: -Innovative pharmaceutical formulations and technologies; -Innovative medical devices with improved therapeutic activity based on co-drugs.

www.project-imode.eu

STAND E21

INSTITUT CARNOT CALYM

The CALYM Carnot Institute brings together 15 research teams specialized in lymphoma, First blood cancer. This academic consortium, without international equivalent, aims at accelerating innovation and its transfer in the lymphoma treatment and diagnosis through a unique R&D offering: from the identification of new biological targets to registration clinical trials.

www.calym.org

STAND H24
INSTITUT CARNOT CURIE CANCER
www.techtransfer.institut-curie.org
STAND H24
Composed of a world-renowned research center and a state-of-the-art hospital group, including 3300 researchers, physicians and caregivers, the Carnot Curie Cancer Institute is a leading player in the fight against cancer. Through its Technology Transfer and Industrial Partnerships Office, the Carnot Curie Cancer ensures that Institut Curie and partners’ inventions nurture from bench to bedside and receive the greatest chance of actually reaching patients.

INSTITUT CARNOT MICA
www.carnot-mica.fr
STAND H24
Specialist in functional materials, surfaces and interfaces, the Carnot MICA Institute supports companies in the design and development of their products and services. With its 17 laboratories and technical centers, all experts in materials and innovative solutions, the Carnot MICA Institute offers companies a comprehensive offering, ranging from basic research to industrial applications.

INSTITUT CARNOT PASTEUR MS
www.research.pasteur.fr/fr/program_project/ms-carnot
Institut Carnot Pasteur Microbes & Santé supports research on infectious and chronic diseases, the role of microbiota in health, and on host-pathogen interactions. Its goal is to help industrial stakeholders develop innovative products in the fields of therapeutics, diagnostics, vaccines and technologies for biology. It consists of six research departments (Cell Biology & Infection, Global Health, Microbiology, Parasites and Insect Vectors, Virology, Mycology) and technological platforms.

INSTITUT CARNOT STAR
www.institutcarnotstar.com
STAND F14
Bringing together a multidisciplinary consortium of 8 laboratories and technological platforms in physics, biology, medicine, computer science and engineering, Carnot STAR offers to the industry a set of complementary scientific expertise and know-how to support its innovation projects in the field « Sport, health and well-being ». STAR offers solutions adapted to needs of industry for:
- Research & Development
- Expertise and advice
- Services.

INSTITUT CARNOT TN@UPSACLAY
www.institutcarnotstar.com
STAND H24
The CEA List, labelled Institut Carnot “Technologies Numériques @UPSaclay” (TN@UPSaclay), conducts research on smart digital systems for industry. Its R&D programs, all with potentially major economic and social implications, focus on the factory of the future, the artificial intelligence and the digital health. By developing cutting-edge technological research, the List helps its industrial partners to enhance their competitiveness through innovation and technology transfer.

IPAZ
www.ipaz.eu
STAND D11
IP-Patents-Trademarks-Design-Strategy-Contracts-Litigation. IPAZ is one of the leading Intellectual Property firms in France. IPAZ provides IP expertise and have a strong record serving companies, research organizations and project leaders. IPAZ will support you to protect and defend your IP rights and help you in IP agreements and in IP litigations, in France and around the world. Our vision of IP integrates the client company’s business strategy to best serve its interests.
IPSIDE www.ipside.com

For 40 years, IPSIDE has supported innovation and supported its clients in intellectual property consulting. Its experts protect your creations, defend your rights, enhance your projects. Large groups, SMEs, startups or independent inventors, IP is a real strategic issue.

IQUALIT www.iqualit.com

In an era of digitalization, Big Data and Data Science, data is a major part of every company. For the Life Sciences, data management is critical. Our duty is to go with every company improving their information system, handling, hosting and processing their data processing with quality assurance. Our services are focused on 3 main expertises: Data Compliance, Data Center and Data to Information. Each service is in compliance with Life Sciences regulations and professional recommendations.

LAXAI LIFE SCIENCES LTD. www.laxai.com

LAXAI is a fully integrated contract research and development organization that delivers solutions in early drug discovery, chemical process development, and GMP manufacturing for pharmaceutical, animal health, and agrochemical industries globally. Our focus is on providing highly efficient and well considered scientific solutions at relatively less time and cost compared to industry standards. Our experience, spanning more than a decade, has enabled us to develop deep expertise in custom NCEs.

LIFESCIENTIS www.lifescientis.com

LifeScients develops innovative and sustainable solutions for encapsulation, vectorization and targeted delivery of compounds. In addition, our expertise in toxicological risk assessment enables us to guide our partners in the definition and implementation of a tailored safety strategy for their products. Committed to improving the performance of products and guaranteeing people safety, LifeScients anticipates the societal and regulatory challenges of the Life Sciences industries.

LINKSIUM www.linksium.fr

Linksium selects and reinforces disruptive technologies generated by deep public research results in Grenoble Alps area. All funded projects have valuable intellectual property inside. At a glance, business players can easily discover and scout most promising technologies and startups that may be the next game changers of the market. Linksium funded 157 technologies with 33 M€, fostering to the creation of 36 startups. 30% of its technologies portfolio (licenses or startups) push back scientific boundaries in health field, and specifically for medical devices.

META GENOPOLIS www.mgps.eu

MetaGenoPolis is the INRA center of shotgun metagenomic in human and animal microbiome research. In collaboration with industries, academics and clinics, MGP conceives and implements projects tailored to the partner’s need. ISO 9001 certified, the protocols and procedures implemented are constantly kept at the cutting edge of technology. MGP proposes quantitative and functional metagenomic to analyze complex microbiome diversity and interactions between gut bacteria and human cells.

MÉTROPOLE AIX-MARSEILLE PROVENCE www.ampmetropole.fr

From basic research to receiving patients, and including medical cosmetology and the expertise from innovative therapies, the metropolis encompasses a very wide scope in the healthcare field. Infectious diseases, immunology, oncology, neurology, innovative therapies: an integrated organization, supported by a very high-level training base and supported by leading companies and laboratories and Eurobiomed Cluster. Backed by publicly-funded research, this sector has extensive international connections.

MI-MABS www.mimabs.org

Mi-mAbs is an innovative integrated immunotechnology [a consortium] center designed to accelerate the development of new immunotherapy antibodies (mAbs, ADC, Bi-specifics) against cancer and inflammatory diseases. Open to the best targets of academic and industrial research, Mi-mAbs generates antibodies and validates them. Mi-mAbs, a multi-disciplinary team, involving experts in hybridoma, in molecular biology, biochemistry, immunochemistry, and in vitro / in vivo immunopharmacology.

MONTPELLIER FRANCE HEALTH HUB www.montpellier-capital-sante.com/en

Montpellier is a territory for research and innovation, with strong entrepreneurial vitality and a long tradition in health, now set on medicine of the future.

A fertilizing environment: presence of leading French research centers, a widely recognized university hospital (CHU), the successful University of Montpellier, the BIC startup incubator ranked 2nd in UBI Global 2018, a site dedicated to companies (Biopôle Euromédecine), the Eurobiomed competitiveness cluster, more than 200 companies...

NEUROSERVICES-ALLIANCE www.neuroservices-alliance.com

We’re a One-Stop Shop CNS CRO for translational data, providing pharma industries with functional readouts in neuro-pharmacology.

We generate data from complementary CNS platforms: in vitro & in vivo CNS Electrophysiology and Behavioral tests. Thanks to our strong college of experts, our functional data from Rodent and Human tissues accelerate CNS and Pain research programs thanks to fast and robust lead selection & optimization, investigation of MOA, and validation of target engagement.

NEURATRIS www.neuratris.com

Achieve your translational neuroscience projects with NeurATRIS one-stop shop. NeurATRIS is a French research infrastructure accelerating translation of research discoveries into medical innovations for the diagnosis and treatment of neurodegenerative diseases.

NeurATRIS gathers a wide range of cutting-edge scientific and clinical expertise, and state-of-the-art platforms (neuroimaging, animal models, aptamers, etc.) covering the entire value chain of translational neuroscience research.

MTD ITS www.mtdits.com

MTD ITs develops innovative and sustainable solutions for encapsulation, vectorization and targeted delivery of compounds. In addition, our expertise in toxicological risk assessment enables us to guide our partners in the definition and implementation of a tailored safety strategy for their products. Committed to improving the performance of products and guaranteeing people safety, MTD ITs anticipates the societal and regulatory challenges of the Life Sciences industries.
Neuro-Sys is a research-intensive innovative CRO company specialized in advanced in vitro models of neurodegenerative diseases and drug development. The company offers disease models and analytical services in the CNS/PNS field such as Alzheimer’s and Parkinson’s disease, ALS. It is specialized in in vitro screening of neuro active molecules and mode of action research. It also accompanies and advises her clients in the drug development from preclinical trials to the clinical phase.

Neuro-Sys
www.neuro-sys.com

Ontoforce NV is a data science company, that creates and implements big data fabrics with potential semantic search technologies, enabling linked data at large scale. It will result in smarter enterprise information management systems, ready for global use at multinationals, SME’s, research institutes, hospitals, and patient organizations. Our mission is to build the best in class, most used linked data platform to find insights in the continuously growing amounts of data efficiently.

Ontoforce NV
www.ontoforce.com

Palm’Data, founded in September 2018, Palm’Data aims to support life sciences companies (pharmaceuticals, cosmetics, medical devices) in the organization, protection and use of regulatory data. With 20 years of expertise in data lifecycle management in the life sciences, we support our clients from the audit phase to employee training to meet GxP requirements whether it is paper data, electronic data, samples or specimens. Palm’Data’s Sophia-Antipolis archiving site has obtained GLP compliance from ANSM.

Palm’Data
www.palm-data.com

Porteghal Accelerator is a biotechnology, nanotechnology, and life sciences startups’ commercialization accelerator as well as an innovation management consulting company based in Iran. Our main mission in Porteghal is to support non-business researchers to form startup teams and to provide commercialization services and seed financing to the startup teams who are looking forward to take the innovation journey & pass the commercialization valley of death. We are a bridge from lab to the market.

Porteghal Accelerator
www.porteghal.org

Nova Biomedical develops, manufactures, and sells advanced technology blood testing analyzers. We employ over 1,200 people, have subsidiaries in 8 countries and more than 91 distributors. Nova is one of the 25 largest in vitro diagnostic companies in the world and the largest privately owned in vitro diagnostic company in the US. Nova manufactures a series of BioProfile® automated cell culture analyzers for rapid analysis of key nutrients, metabolites, pH, gases, and cell density/cell viability.

Nova Biomedical
www.novabio.us

Oroxcell is entering the forthcoming decade with novel assays using validated 3D-Organotypic Human Models based assays, for Efficacy, ADME and Safety, while maintaining its GLP compliance status. Areas of expertise: Pharma, Nutrition Health, Dermato-Cosmetic, Medical Device and chemicals.

Oroxcell
www.oroxcell.com

PMC Isochem offers contract research, development, custom manufacturing, catalogue products and innovative solutions for Pharmaceutical companies worldwide. Drug delivery solutions: TPGS-1000 NF USP for poorly soluble drug formulation and Polyamino acid based solutions for Nano Encapsulation and Polymer Drug Conjugates. CDMO services: GMP industrial exclusive custom synthesis and provides tailor made services from development to production. 3 FDA audited manufacturing plants. Generic APIs: 20 generic API formulations and Polyamino acid based solutions for pharmaceutical industries, Oroxcell is entering the forthcoming decade with novel assays using validated 3D-Organotypic Human Models based assays, for Efficacy, ADME and Safety, while maintaining its GLP compliance status. Areas of expertise: Pharma, Nutrition Health, Dermato-Cosmetic, Medical Device and chemicals.

PMC Isochem
www.pmcisochem.fr

Prodecys Consulting firm dedicated to Project Management, we support companies to optimize their projects around 3 key pillars: Project Management Expertise, Training, Implementation of Project management & collaborative tools. We come from a Pharmaceutical Industry PMO. Our consultants are all experienced in international project management and certified on international project management standards. In a nutshell, Prodecys is a concentrate of complementary skills within an agile structure.

Prodecys
www.prodecys.com

Novavia is an independent player in histology since 1996. Specialized in Toxicology/Pre-clinical, Pharmacology, Academic Research, Dermocosmetics, Novavia is committed to its customers in terms of quality and deadlines. Our expertise allows our teams to offer you a personalized offer (customized protocols respecting your specifications), a guarantee of conformity (GLP accreditation, 100% control of the slides) as well as additional services such as: the scanning of your slides and IHC.

Novavia
www.labo-novavia.com

Ouest Valorisation is a Société d’Accélération du Transfert de Technologies or Technology Transfer Acceleration Company – TTO. Our mission is to add value to the results produced by public research laboratories, in Brittany and the Pays de la Loire, and to offer attractive innovation resources to socio-economic actors.

Ouest Valorisation
www.ouest-valorisation.fr

Polepharma is the first pharmaceutical alliance in Europe, covering 3 regions (Centre-Val de Loire, Normandie and Ile de France) that ensures 53% of drug production in France. Its network relies on a team of experts who aim at stimulating industrial and economic development of the pharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the “Made in France”.

Polepharma
www.polepharma.com

Priority Health Sud Region is the 2nd health scientific research center, 2nd french region for innovation patents et clinical trials. Region has one of the heaviest french hospital network, a large variety of research platforms and a strong dynamic in clinical, industrial and academic research. The research laboratories are highly renowned in immuno-oncology with Marseille Immunopole cluster, infectious and tropical diseases with Institut Hospitalo-universitaire Méditerranée Infection, rare and orphan diseases and neurosciences.

Priority Health Sud Region
www.mareregionsud.fr
SATTs are French private TTOs, shared between several public research organizations, created to develop and commercialize research results to be transformed into innovative products. They evaluate, market and license technology from French Universities and Public Research Organizations. Bringing together professionalism, expertise and financing, SATTs come along the transfer chain according to the needs of industry. By increasing the Technology Readiness Levels, they also participate in reducing company risks.

**SATT Nord**
SATT Nord accelerates technology transfer from public research to the market. SATT Nord covers the whole value chain of technology transfer, increasing the awareness of researchers to innovation, sourcing high potential inventions in academic research labs, cofunding private-public collaborations, financing proof of concept and prototyping projects, as well as marketing “ready to industrialize” technologies through licensing out agreements, or creating start-up businesses.

**S&P Brain**
The company is an Italian academic spinoff, located in Northern Italy (Piedmont region), that was founded in 2016 by a group of senior academic neuroscientists. It offers preclinical studies spanning from a wide range of behavioral tests to models of neurological injuries and degenerative disorders to cardiovascular, endocrine and metabolic measures to toxicological studies. The company seeks industrial, R&D centers for technical, research cooperation or services agreements.

**Sciomics GmbH**
Sciomics offers high-content analysis services for > 1,000 proteins in a single assay including changes of their post-translational modification status. Typical applications for the platform are:
- Analysis of pathway activity and disease mechanisms;
- Drug MOA studies;
- Novel drug targets discovery;
- Identification and verification of protein biomarkers. Our immuno-based assays guarantee robust and reproducible results which can easily be translated into clinical assays.

**SMALTIS**
SMALTIS is a French laboratory expert in microbiology, delivering high added value and personalized technological solutions to support the development of health products, from research to clinical trials. Its fields of expertise are the fight against antibiotic resistance, the exploration of microbiota and the strain engineering for research and bioproduction applications. SMALTIS’ strengths lie on flexibility, reactivity and partnership.

**SOLADIS**
Soladas is a consulting company specialized in health data, composed of 100 expert resources in France, Switzerland, US and Canada. Supporting life science actors, Soladas provides in-depth evaluation services (through the CRO Soladis Clinical Studies) as well as methodological and analytical assistance with biostatistical consulting and Machine Learning / AI development.

**Syncrosome**
Syncrosome offers relevant disease models, cutting-edge techniques, specific Biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds. Our main activities consist in:
- In vivo Drug Efficacy Studies: CNS, Cardiometabolism, Gastro and Respiratory
- CNS-PK with a special focus in the study of the Blood Brain Barrier passage and/or Neurotransmitter monitoring.
- Early (PK/PD) on rodents and non-rodents species.
SYNEOS HEALTH
www.syneoshealth.com
SYNEOS HEALTH: Translational Science, Sophia-Antipolis, France, provides a suite of integrated scientific capabilities from molecular characterization to lead candidate selection, to biomarker validation and model-based drug development, supporting sponsor’s drug development. A team of 80+ scientists with expertise in Biomarkers, Pharmacology, DMPK for General medicine, Oncology, Immuno-Inflammatory conditions works in a 31,500sq Laboratory space, with more than 200 state-of-the-art equipment.

TOULOUSE TECH TRANSFER
www.toulouse-tech-transfer.com
Toulouse Tech Transfer core business is to invest in technology-maturing programs based on academic research results of the Midi-Pyrénées region, which cover: - IP and legal management, in order to create more value through patents and know-how; - Marketing to identify which market mix should be targeted; - Technical operations to design and finance relevant proof of concept programs to reach an attractive level for businesses.
The objective is to license the matured technologies and products to businesses.

TREMPIN CARNOT INTERFACES
www.carnot-interfaces.fr
Carnot INTERFACES brings together 5 laboratories of excellence from SORBONNE UNIVERSITE and offers you its expertise in collaborative research specialized in all digital’s areas. In Medtech: biomedical imaging, big data, robotics, AI, IOT, knowledge engineering...

TREMPIN CARNOT IPGG MICROFLUIDIQUE
www.institut-ppg.fr/Presentation-du-Trempin-Carnot-IPGG_266.html
The Institute Pierre-Gilles de Gennes (IPGG) is an Institute of excellence dedicated to microfluidics. Microfluidic is the science of handling fluids on a micrometric scale. Trempin Carnot IPGG ambition is to bring “microfluidic revolution” to the service of industry with a proven and high level R&D competencies. Entrepreneurs, professionals and experts, if you are curious to learn more about the potential offered by microfluidic and how to partner with us, come and meet us!

THE MABEXPERTS GROUP: RD-BIOTECH, DIACLONE, SYNABS AND QVQ
www.mabexperts.com
mABexperts, a team of 4 companies based on complementary expertise in the field of Antibody Engineering, with a large panel of custom services and products.
RD-BIOTECH: High added value custom services in Immunology, Genetic and Cell Engineering: development and biomanufacturing of plasmid DNA, monoclonal antibodies, recombinant proteins and antibodies (Fab, bsAbs, scFv...). Analytical platform for proteins characterization and its fastELISA kits range.
DIACLONE: Centre of excellence in Monoclonal Antibody and Immunoassays development, with an extensive product portfolio of mAbs, ELISA and ELISPOT kits (such as its murine and human IFN- ELISPOT). Expertise in antibody development (hybridoma and phage display) and biosays services.
SYNABS: A catalogue of anti-species secondary antibodies (anti-human, mouse, rat, bovine, rabbit...) and an extensive expertise in the development of monoclonal antibodies in mice, as well as in rats (LOU rats) and guinea pigs using highly innovative technologies.
QVQ: Recognized expertise in the phage display development of antibody fragments (VHH) from llamas. In addition to its services, offers a range of exclusive and high-quality VH-Hls.

BIOENGINEERING: CARNOT INTERFACES
www.tcd.ie/innovation/industry
Trinity College Dublin is Ireland’s highest ranked university. Trinity is seeking industry partners in the areas of biomedical science, bioengineering, ehealth, immunology/inflammation and infection, neuroscience and pharmaceutical science, rare diseases, cancer and ageing. Our researchers want to work on collaborative R&D projects, tackling industry relevant research challenges.

UNIVERSITÉ CÔTE D’AZUR
www.univ-cotedazur.fr
Université Côte d’Azur (UCA) is a recently created cluster of higher education establishments that brings together the major players in education and research on the French Riviera. UCA aims to develop a new 21st-century model for French universities, based on new interactions between disciplines and coordination between research, teaching, and innovation. In 2016, UCA won a prestigious “IDEX” award from the French government, placing it among the top 10 world-class universities in France.
Xell AG
www.xell.ag

Xell is an innovative partner for the biotech and pharmaceutical industry, providing efficient solutions in cell culture technology. Xell has developed a range of customized and commercial culture media and feed supplements (CD, AOF) for the most commonly used mammalian cell types. Apart from our media platform we offer analytical services (e.g. our powerful spent media analysis) as well as cell culture and process services to better understand cell behaviour and optimize cultivation processes.

YesMyPatent
www.yesmypatent.com

YesMyPatent is a service of the French Patent Law Firm Touroude & Associates, aiming to democratize patent filling in Europe. Our offer is unique and based on 2 criteria: the expertise of our 25-collaborators teams, all Patent Attorneys accredited by the INPI and/or the European Patent Office, as well as a modern and efficient digital platform.

Ximbio
www.ximbio.com

Ximbio is a non-profit that works to commercialise life science reagents of all kinds at scale. Ximbio is part of Cancer Research UK and works with tech transfer offices globally to find, store, produce, market, sell and license research reagents. Ximbio also works with life science reagent supply companies, as well as pharma companies, to supply high quality reagents for internal research use or onward sale.

Xpress Biologics
www.xpress-biologics.com

Xpress Biologics is a Contract Development and Manufacturing Organization (CDMO) specialized in the production of Biologics (proteins, antibody fragments and DNA) for preclinical applications specific to the therapeutic, vaccine and diagnostic markets. The production scale, from 100 mg to 50 g and the quality of the biologics (R&D and GMP-like grades) are adapted for in vitro and in vivo preclinical validation of the biologics.

ZwickRoell
www.zwickroell.com/fr-fr/industrie-médicale

ZwickRoell is the world’s leading supplier of materials testing machines. Our materials testing machines are used worldwide in R&D and quality assurance in more than 20 industries. ZwickRoell has stood for reliable test results, excellent service, quality and reliability in materials and components testing. ZwickRoell has all the tools needed to meet requirements of the medical industry: clean room requirements, DQ IQ OQ qualification, Expanded Traceability, climate chambers, dynamic testing.
NOTES
A unique ecosystem to make healthcare revolution happen in Europe

VISION

From precision engineering to smart connected HealthTech, and from academic research to the clinic, NOBEL is creating an European HealthTech ecosystem, for the convergence of nanomedicine with photonics, robotics, biomaterial, smart systems, eHealth and Textile.

MISSIONS

✓ BUILDING AN ECOSYSTEM: NOBEL organizes multiple events to create a unique meeting place for all the European HealthTech stakeholders.

✓ SHAPING A STRATEGY: NOBEL builds a common vision for the future of HealthTech in Europe, integrating the separate roadmaps of emerging medical technologies.

✓ ACCELERATING INNOVATION: NOBEL manages the HealthTech Translation Advisory Board, a premium service offering tailored support to the selected HealthTech innovations, free-of-charge for beneficiaries.

www.nobel-project.eu

The NOBEL Coordination and Support Action has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement no 766492.

✓ Coordinator: European Technology Platform on Nanomedicine (ETPN).
✓ Core Partners: CEA, MedTech Europe, Bioanalytik Muenster, VDI/VDE/IT, TecMinho, Fondazione Don Gnocchi, Tyndall National Institute and Nanobiotix (as a third party).
✓ Associated partners: national nanomedicine platforms and other emerging technologies ETPs.
FLOOR PLAN & LIST
The leading European partnering event for early-stage deals and investment rounds in the Life Sciences field

DECEMBER 1ST & 2ND 2020
STRASBOURG FRANCE

Organisers:

Institutional partners: